|
3572.
|
|
11 p, 1.4 MB |
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19
/
Barbui, Tiziano (Papa Giovanni XXIII Hospital. FROM Research Foundation) ;
De Stefano, Valerio (Fondazione Policlinico "A. Gemelli" IRCCS. Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University) ;
Alvarez-Larran, Alberto (Hospital Clínic i Provincial de Barcelona) ;
Iurlo, Alessandra (Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico. Hematology Division) ;
Masciulli, Arianna (Papa Giovanni XXIII Hospital. FROM Research Foundation) ;
Carobbio, Alessandra (Papa Giovanni XXIII Hospital. FROM Research Foundation) ;
Ghirardi, Arianna (Papa Giovanni XXIII Hospital. FROM Research Foundation) ;
Ferrari, Alberto (Papa Giovanni XXIII Hospital. FROM Research Foundation) ;
Cancelli, Valeria (Spedali Civili) ;
Elli, Elena Maria (Ospedale San Gerardo (Itàlia)) ;
Andrade-Campos, Marcio Miguel (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Kabat, Mercedes Gasior (Hospital Universitario La Paz (Madrid)) ;
Kiladjian, Jean-Jaques (Hospital Saint-Louis) ;
Palandri, Francesca (Azienda Ospedaliero-Universitaria di Bologna) ;
Benevolo, Giulia (AOU Città della Salute e della Scienza di Torino) ;
Garcia-Gutierrez, Valentin (Hospital Universitario Ramón y Cajal (Madrid)) ;
Fox, Maria Laura (Vall d'Hebron Institut d'Oncologia) ;
Foncillas, Maria Angeles (Hospital Universitario Infanta Leonor) ;
Morcillo, Carmen Montoya (Complejo Hospitalario Universitario de Albacete) ;
Rumi, Elisa (University of Pavia. Department of molecular medicine) ;
Osorio, Santiago (Hospital General Universitario Gregorio Marañón) ;
Papadopoulos, Petros (Hospital Clínico San Carlos (Madrid)) ;
Bonifacio, Massimiliano (Ospedale Policlinico "G.B. Rossi", Borgo Roma) ;
Quiroz Cervantes, Keina (Hospital Universitario de Móstoles (Madrid)) ;
Serrano, Miguel Sagues (Hospital de Sant Joan Despí Moisès Broggi) ;
Carreño-Tarragona, Gonzalo (Hospital Universitario 12 de Octubre (Madrid)) ;
Sobas, Marta Anna (Wroclaw Medical University. Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation) ;
Lunghi, Francesca (IRCCS Ospedale San Raffaele) ;
Patriarca, Andrea (AOU Maggiore della Carità, Novara, Italy) ;
Elorza, Begoña Navas (Hospital Moncloa, Madrid, Spain) ;
Angona, Anna (Hospital Universitari de Girona Doctor Josep Trueta) ;
Mazo, Elena Magro (Hospital Universitario Príncipe de Asturias (Alcalá de Henares, Madrid)) ;
Koschmieder, Steffen (RWTH Aachen University. Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine) ;
Carli, Giuseppe (Ospedale San Bortolo) ;
Cuevas, Beatriz (Hospital Universitario de Burgos) ;
Hernandez-Boluda, Juan Carlos (Hospital Clínic Universitari (València)) ;
Abadia, Emma Lopez (Hospital General Universitario de Elche) ;
Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Guglielmelli, Paola (University of Florence. Center Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, Azienda Ospedaliera Universitaria Careggi) ;
Garrote, Marta (Hospital Clínic i Provincial de Barcelona) ;
Cattaneo, Daniele (Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico. Hematology Division) ;
Daffini, Rosa (Spedali Civili) ;
Cavalca, Fabrizio (Ospedale San Gerardo (Itàlia)) ;
Bellosillo Paricio, Beatriz (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Benajiba, Lina (Hospital Saint-Louis) ;
Curto-Garcia, Natalia (Guy's and St. Thomas' NHS Foundation Trust) ;
Bellini, Marta (ASST Papa Giovanni XXIII, Bergamo, Italy) ;
Betti, Silvia (Fondazione Policlinico "A. Gemelli" IRCCS. Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University) ;
Harrison, Claire (Guy's and St. Thomas' NHS Foundation Trust) ;
Rambaldi, Alessandro (Università degli Studi di Milano) ;
Vannucchi, Alessandro Maria (University of Florence. Center Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, Azienda Ospedaliera Universitaria Careggi) ;
Universitat Autònoma de Barcelona
In a multicenter European retrospective study including 162 patients with COVID-19 occurring in essential thrombocythemia (ET, n = 48), polycythemia vera (PV, n = 42), myelofibrosis (MF, n = 56), and prefibrotic myelofibrosis (pre-PMF, n = 16), 15 major thromboses (3 arterial and 12 venous) were registered in 14 patients, of whom all, but one, were receiving LMW-heparin prophylaxis. [...]
2021 -  10.1038/s41408-021-00417-3
Blood Cancer Journal, Vol. 11 (february 2021)
|
|
|
3573.
|
|
8 p, 452.0 KB |
Prognostic value of lymphocyte-to-monocyte ratio previously determined to surgery in patients with non-metastatic renal cell carcinoma
/
Garcia-Rojo, Dario (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Prera, Angel (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Muñoz-Rodríguez, Jesús (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Oliva, Joan Carles (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Dominguez-Garcia, Arturo (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Prats, Joan (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Universitat Autònoma de Barcelona.
Departament de Cirurgia
The prognostic value of pretreatment lymphocyte to monocyte ratio in patients with renal cell carcinoma and, especially, in non-metastatic patients remains controversial. We conducted a PRISMA-compliant meta-analysis to systematically assess the prognostic value of LMR in patients with non-metastatic RCC. [...]
2021 - 10.1097/MD.0000000000024152
Medicine, Vol. 100 N.3 (january 2021)
|
|
|
3574.
|
|
13 p, 5.4 MB |
Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity
/
Zanetti, S. R. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Romecín, Paola Alejandra (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Vinyoles, Meritxell (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Juan, Manel (Hospital Clínic i Provincial de Barcelona) ;
Fuster, José Luis (Instituto Murciano de Investigación Biosanitaria) ;
Camós, Mireia (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Querol, Sergi (Blood and Tissue Bank) ;
Delgado, M. (Instituto de Parasitología y Biomedicina "López-Neyra") ;
Menéndez Bujan, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Universitat Autònoma de Barcelona
Background Although adoptive transfer of CD19-directed chimeric antigen receptor (CAR) T-cells (CD19-CAR T-cells) achieves high rates of complete response in patients with B-cell acute lymphoblastic leukemia (B-ALL), relapse is common. [...]
2020 - 10.1136/jitc-2020-001419
Journal for immunotherapy of cancer, Vol. 8 Núm. 2 (31 2020) , p. e001419
|
|
|
3575.
|
|
14 p, 572.1 KB |
Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer
/
Frigola Rissech, Joan (Vall d'Hebron Institut d'Oncologia) ;
Navarro, Alejandro (Vall d'Hebron Institut d'Oncologia) ;
Carbonell, Caterina (Vall d'Hebron Institut d'Oncologia) ;
Callejo, Ana (Vall d'Hebron Institut d'Oncologia) ;
Iranzo, Patricia (Vall d'Hebron Institut d'Oncologia) ;
Cedrés, Susana (Vall d'Hebron Institut d'Oncologia) ;
Martinez-Marti, Alex (Vall d'Hebron Institut d'Oncologia) ;
Pardo Aranda, Nuria (Vall d'Hebron Institut d'Oncologia) ;
Saoudi-Gonzalez, Nadia (Vall d'Hebron Institut d'Oncologia) ;
Martinez, Débora (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Jiménez, José (Vall d'Hebron Institut d'Oncologia) ;
Sansano, Irene (Hospital Universitari Vall d'Hebron) ;
Mancuso, Francesco M. (Vall d'Hebron Institut d'Oncologia) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Montuenga, Luis M. (Instituto de Investigación Sanitaria de Navarra) ;
Sanchez-Cespedes, Montse (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Prat, Aleix (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ;
Felip, Enriqueta (Vall d'Hebron Institut d'Oncologia) ;
Amat, Ramon (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
Immunotherapy has transformed advanced non-small cell lung cancer (NSCLC) treatment strategies and has led to unprecedented long-lasting responses in some patients. However, the molecular determinants driving these long-term responses remain elusive. [...]
2020 - 10.1002/1878-0261.12891
Molecular Oncology, 2020
|
|
|
3576.
|
|
11 p, 5.7 MB |
Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope
/
Velasco-Hernández, Talia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Zanetti, S. R. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Roca Ho, Heleia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Gutiérrez-Agüera, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Petazzi, Paolo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sánchez-Martínez, D. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Molina, Oscar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Baroni, Matteo Libero (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Fuster, José Luis (Sección de Oncohematología Pediátrica. Hosp. Clin. Universitario Virgen de la Arrixaca and Instituto Murciano de Investigacion Biosanitaria) ;
Ballerini, Paola (Department of Pediatric Hemato-oncology. Armand-Trousseau Childrens Hospital) ;
Bueno, Clara (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Fernández-Fuentes, Narcís (Universitat de Vic - Universitat Central de Catalunya) ;
Engel, P. (Universitat de Barcelona. Departament de Biomedicina) ;
Menéndez Bujan, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Universitat Autònoma de Barcelona
Background There are few therapeutic options available for patients with B-cell acute lymphoblastic leukemia (B-ALL) relapsing as CD19 - either after chemotherapy or CD19-targeted immunotherapies. CD22-chimeric antigen receptor (CAR) T cells represent an attractive addition to CD19-CAR T cell therapy because they will target both CD22 + CD19 - B-ALL relapses and CD19 - preleukemic cells. [...]
2020 - 10.1136/jitc-2020-000896
Journal for immunotherapy of cancer, Vol. 8 Núm. 2 (november 2020) , p. e000896
|
|
|
3577.
|
|
12 p, 1.8 MB |
Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option : a cross-study comparison of the CANDOR and EQUULEUS studies
/
Leleu, Xavier (Service d'Hématologie et Thérapie cellulaire. CHU and Inserm) ;
Beksac, M. (Department of Hematology. Ankara University) ;
Chou, T. (Niigata Cancer Center Hospital) ;
Dimopoulos, Meletios (Hematology and Medical Oncology. Department of Clinical Therapeutics. National and Kapodistrian University of Athens School of Medicine) ;
Yoon, S. S. (Department of Internal Medicine. Seoul National University) ;
Prince, H. M. (Epworth Healthcare and Sir Peter MacCallum Department of Oncology. University of Melbourne) ;
Pour, L. (University Hospital Brno (República Txeca)) ;
Shelekhova, T. (Clinic of Professional Pathology) ;
Chari, Ajai (Icahn School of Medicine at Mount Sinai (Nova York, Estats Units d'Amèrica). Tisch Cancer Institute) ;
Khurana, M. (Clinical Development. Oncology. Amgen Inc) ;
Zhang, J. (Global Biostatistical Science. Amgen Inc) ;
Obreja, M. (Global Biostatistical Science. Amgen Inc) ;
Qi, M. (Hematology and Oncology. Janssen Research and Development. LLC) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Siegel, D. (John Theurer Cancer Center. Hackensack University Medical Center) ;
Universitat Autònoma de Barcelona
The regimen of carfilzomib, daratumumab, and dexamethasone (KdD) shows activity in patients with relapsed/refractory multiple myeloma. KdD at the twice-weekly 56 mg/m carfilzomib dose (KdD56) was used in the randomized phase 3 CANDOR study (NCT03158688), whereas KdD at the once-weekly 70 mg/m carfilzomib dose (KdD70) was used in the phase 1 b EQUULEUS study (NCT01998971). [...]
2020 - 10.1080/10428194.2020.1832672
Leukemia and Lymphoma, 2020
|
|
|
3578.
|
|
13 p, 1.6 MB |
Pembrolizumab as consolidation strategy in patients with multiple myeloma : Results of the GEM-pembresid clinical trial
/
Puig, N. (Centro de Investigación Biomédica en Red de Cáncer) ;
Corchete Sánchez, Luis Antonio (Centro de Investigación Biomédica en Red de Cáncer) ;
Pérez-Morán, J. J. (Centro de Investigación Biomédica en Red de Cáncer) ;
Dávila, J. (Complejo Asistencial de Ávila. Hematology Department) ;
Paíno, T. (Centro de Investigación Biomédica en Red de Cáncer) ;
de la Rubia, Javier (Hospital Universitari Doctor Peset (València)) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Martín-Sánchez, J. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
De Arriba, Felipe (Hospital Universitario Virgen de la Arrixaca (Múrcia)) ;
Bladé Creixenti, Juan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Blanchard, María Jesús (Hospital Universitario Ramón y Cajal (Madrid)) ;
González-Calle, Verónica (Centro de Investigación Biomédica en Red de Cáncer) ;
García-Sanz, Ramón (Centro de Investigación Biomédica en Red de Cáncer) ;
Paiva, Bruno (Clínica Universidad de Navarra. Centro de Investigación Médica Aplicada) ;
Lahuerta, J. J. (Centro de Investigación Biomédica en Red de Cáncer) ;
San-Miguel, J. F. (Clínica Universidad de Navarra. Centro de Investigación Médica Aplicada) ;
Mateos, M. V. (Centro de Investigación Biomédica en Red de Cáncer) ;
Ocio, E. M. (Instituto de Investigación Sanitaria Valdecilla (Santander, Cantàbria)) ;
Universitat Autònoma de Barcelona
PD1 expression in CD4 and CD8 T cells is increased after treatment in multiple myeloma patients with persistent disease. The GEM-Pembresid trial analyzed the efficacy and safety of pembrolizumab as consolidation in patients achieving at least very good partial response but with persistent measurable disease after first-or second-line treatment. [...]
2020 - 10.3390/cancers12123615
Cancers, Vol. 12 Núm. 12 (december 2020) , p. 1-13
|
|
|
3579.
|
|
15 p, 2.9 MB |
MethCORR modelling of methylomes from formalin-fixed paraffin-embedded tissue enables characterization and prognostication of colorectal cancer
/
Mattesen, T. B. (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Rasmussen, M. H. (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Sandoval, J. (Instituto de Investigación Sanitaria La Fe) ;
Ongen, H. (Genetic Medicine and Development. University of Geneva Medical School-CMU) ;
Árnadóttir, S. S. (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Gladov, J. (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Martínez Cardús, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Castro de Moura, Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Madsen, A. H. (Department of Surgery. Hospitalsenheden Vest) ;
Laurberg, S. (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Dermitzakis, Emmanouil T (University of Geneva Medical School) ;
Esteller, M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Andersen, Claus Lindbjerg (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Bramsen, Jesper Bertram (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Universitat Autònoma de Barcelona
Transcriptional characterization and classification has potential to resolve the inter-tumor heterogeneity of colorectal cancer and improve patient management. Yet, robust transcriptional profiling is difficult using formalin-fixed, paraffin-embedded (FFPE) samples, which complicates testing in clinical and archival material. [...]
2020 - 10.1038/s41467-020-16000-6
Nature communications, Vol. 11 Núm. 1 (january 2020) , p. 2025
|
|
|
3580.
|
|
24 p, 2.2 MB |
The evolution of relapse of adult T cell acute lymphoblastic leukemia
/
Sentís, I. (Institut de Recerca Biomèdica) ;
González, S. (Institut de Recerca Biomèdica) ;
Genescà, Eulàlia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
García-Hernández, Violeta (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Muiños, Ferran (Institut de Recerca Biomèdica) ;
González Gil, Celia. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
López-Arribillaga, E. (Institut de Recerca Biomèdica) ;
González, Jéssica (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Fernández Ibarrondo, Lierni (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Mularoni, L. (CMR[B] Center of Regenerative Medicine) ;
Espinosa, Lluís (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Bellosillo Paricio, Beatriz (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bigas Salvans, Anna (Institut Hospital del Mar d'Investigacions Mèdiques) ;
González-Pérez, A (Universitat Pompeu Fabra) ;
Lopez-Bigas, N. (Institució Catalana de Recerca i Estudis Avançats) ;
Universitat Autònoma de Barcelona
Background: Adult T cell acute lymphoblastic leukemia (T-ALL) is a rare disease that affects less than 10 individuals in one million. It has been less studied than its cognate pediatric malignancy, which is more prevalent. [...]
2020 - 10.1186/s13059-020-02192-z
Genome biology, Vol. 21 Núm. 1 (december 2020) , p. 284
|
|
|
3581.
|
|
18 p, 4.0 MB |
Targeting OGG1 arrests cancer cell proliferation by inducing replication stress
/
Visnes, T. (Sintef Industry. Department of Biotechnology and Nanomedicine) ;
Benítez-Buelga, Carlos (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Cázares-Körner, A. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Sanjiv, K. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Hanna, Bishoy (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Mortusewicz, O. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Rajagopal, Veera M (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Albers, J. J. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Hagey, D. W. (Karolinska Institutet (Estocolm, Suècia). Department of Laboratory Medicine) ;
Bekkhus, T. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Eshtad, S. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Baquero, Juan Miguel (Centro Nacional de Investigaciones Oncológicas) ;
Masuyer, G. (University of Bath. Department of Pharmacy and Pharmacology) ;
Wallner, O. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Müller, S. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Pham, T. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Göktürk, C. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Rasti, A. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Suman, S. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Torres, Raul (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sarno, A. (Sintef Ocean. Department of Environment and New Resources) ;
Wiita, E. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Homan, E. J. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Karsten, S. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Marimuthu, K. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Michel, M. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Koolmeister, T. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Scobie, M. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Loseva, O. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Almlöf, I. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Unterlass, J. E. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Pettke, A. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Boström, J. (Karolinska Institutet (Estocolm, Suècia). Department of Laboratory Medicine) ;
Pandey, M. (University of Sheffield. Weston Park Cancer Centre) ;
Gad, H. (University of Sheffield. Weston Park Cancer Centre) ;
Herr, P. (University of Sheffield. Weston Park Cancer Centre) ;
Jemth, A. S. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
El Andaloussi, S. (Karolinska Institutet (Estocolm, Suècia). Department of Laboratory Medicine) ;
Kalderén, C. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Rodriguez-Perales, Sandra (Centro Nacional de Investigaciones Oncológicas) ;
Benítez, J. (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Krokan, H. E. (Research and Innovation in Central Norway) ;
Altun, M. (Karolinska Institutet (Estocolm, Suècia). Department of Laboratory Medicine) ;
Stenmark, P. (Lund University. Department of Experimental Medical Science.) ;
Berglund, U. W. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Helleday, Thomas (University of Sheffield.Weston Park Cancer Centre) ;
Universitat Autònoma de Barcelona
Altered oncogene expression in cancer cells causes loss of redox homeostasis resulting in oxidative DNA damage, e. g. 8-oxoguanine (8-oxoG), repaired by base excision repair (BER). PARP1 coordinates BER and relies on the upstream 8-oxoguanine-DNA glycosylase (OGG1) to recognise and excise 8-oxoG. [...]
2021 - 10.1093/nar/gkaa1048
Nucleic acids research, Vol. 48 Núm. 21 (february 2021) , p. 12234-12251
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
